Overview

Remimazolam NeuroImaging

Status:
RECRUITING
Trial end date:
2027-12-02
Target enrollment:
Participant gender:
Summary
This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Keith M Vogt
Collaborator:
National Institute of General Medical Sciences (NIGMS)
Treatments:
remimazolam